In Vivo Effects of Recombinant Human Interleukin 2 on Antitumor and Antiviral Natural Immunity in Induced or Natural Murine Immunodeficiency States

Cancer Research

Volumn 48, Issue 21, 1988, Pages 6081-6089

  Butler, L D ^a   Browne, C P ^a   Layman, N K ^a   Riedl, P ^a   Marder, P ^a   Tang, J ^a   DeLong, D ^a   Manetta, J ^a   Bobbitt, L ^a   Strnad, J ^a   Gadski, R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CYTOCHEMISTRY; IMMUNE DEFICIENCY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G(M1) GANGLIOSIDE; GLYCOSPHINGOLIPIDS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; VIRUS DISEASES; WHOLE-BODY IRRADIATION;

EID: 0023723830     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Taniguchi, T., Matsui, H., Fujita, T., Takaoka, C., Kashima, N., Yoshimoto, R., and Hamuro, J. Structure and expression of a cloned cDNA for human interleukin-2. Nature (Lond.), 302: 305-310, 1983.
2. Gray, P. W., and Goeddel, D. V. Structure of the human immune interferongene. Nature (Lond.). 298: 859-863, 1982.
3. Henney, C. S., Kuribayashi, K., Kern, D. E., and Gillis, S. Interleukin-2 augments natural killer activity. Nature (Lond.), 291: 335-338, 1981.
4. Cheever, M. A., Greenberg, P. D., Fefer, A., and Gillis, S. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2. J. Exp. Med., 755: 968-980, 1982.
5. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. Lymphokine activated killer phenomenon: Lysis of natural killer resistant fresh autologous tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes. J. Exp. Med., 155: 1823-1841, 1982.
6. Kedar, E., and Herberman, R. B. Induction of NK-like anti-tumor activity in vitro and in vivo by IL-2. In: R. B. Herberman (ed.), NK cells and other natural effector cells, pp. 859-871. New York: Academic Press, 1982.
7. Grimm, E. A., Ramsey, K. M., Mazumder, A., Wilson, D. J., Djeu, J. Y., and Rosenberg, S. A. Lymphokine activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes memory cytotic thymus derived lymphocytes and natural killer cells. J. Exp. Med., 757: 884-897. 1983.
8. Hefeneider, S. H., Gonion, P. J., Henney, C. S., and Gillis, S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J. Immunol., 130: 222-227, 1983.
9. Teh, H-S., and Yu, M. Activation of nonspecific killer cells by interleukin 2-containing supernatants. J. Immunol., 131: 1827-1833, 1983.
10. Merluzzi, V. J., Savage, D. M., Mertelsmann, R., and Weite, K. Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin J. Cell Immunol., 39: 3647-3654, 1984.
11. Donohue, J. H., Rosenstein, M., Chang, A. E., Lotze, M. T., Robb, R. J., and Rosenberg, S. A. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J. Immunol., 132: 2123-2128, 1984.
12. Mazumder, A., and Rosenberg, S. A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukine-2. J. Exp. Med., 159: 495-507, 1984.
13. Donohue, J. H., Lotze, M. T., and Robb, R. J., et al. In vivo administration of purified jurkat derived interleukin 2 in mice. Cancer Res., 44: 2380-2386, 1984.
14. Herberman, R. B. Summary: Potential of interleukin-2 for therapy of cancer. J. Biol. Response Modif., 3: 527-532, 1984.
15. Chang, A., Hyatt, C. L., and Rosenberg, S. A. Systemic administration of recombinant interleukin-2 in mice. J. Biol. Response Modif., 3: 561-572, 1984.
16. Talmadge, J. E., Dennis-Tail, S., Schneider, M. E., Meeker, A., Adams, J., Ortaldo, J., and Wiltrout, R. H. In vivo stimulation of murine lymphocytes by human recombinant interleukin-2 (R-IL-2). In: A. E. Reif and M. S. Mitchell (eds.). Immunity to Cancer. New York: Academic Press, 1984.
17. Talmadge, J. E. Immunoregulation and immunostimulation of murine lymphocytes by recombinant interleukin-2. J. Biol. Response Modif., 4: 18-34, 1985.
18. Sayers, T., Rossiter, H., Chung, J., Hren, A., and Armerding, D. In vivo activation of murine natural killer cell functions by human recombinant DNA Interleukin 2. Immunobiology. 169(3): 303-318, 1985.
19. Tang, J., Delong, D. C., Marder, P., Butler, L. D., and Ades, E. W. Identification of functional subpopulations of murine natural killer cells based on their cell surface asialo GM1 phenotype. Cell. Immunol., 96: 386-397, 1985.
20. Lotze, M. T., and Rosenberg, S. A. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology, 172(3-5): 420-437, 1986.
21. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., and Vetto, J. T., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Eng. J. Med., 313: 1485-1492, 1985.
22. Lotze, M. T., Chang, A. E., Seipp, C. A., Simpson, C., Vetto, J. T., and Rosenberg, S. A. High dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity and histologie findings. J. Am. Med. Assoc., 256: 3117-3124, 1986.
23. Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., and Rosenberg, S. A. Clinical effects and toxicity of interleukin 2 in patients with cancer. Cancer (Phila.), 58: 2764-2772, 1986.
24. Merluzzi, V. J., Weite, K., Savage, D. M., Last-Barney, K., and Mertelsmann, R. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J. Immunol., 131: 806-809, 1983.
25. Flomenberg, N., Weite, K., and Mertelsmann, R., et al. Immunologie effects of interleukin-2 in primary immunodeficiency diseases. J. Immunol., 130: 2644-2650. 1983.
26. Rook, A. H., Masur, H., and Lane, H. C., et al. Interleukin 2 enhances the depressed natural killer and cytomegalovirus specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J. Clin. Invest., 72: 398-407. 1983.
27. Conlon, P. J., Washkewicz, T. L., Mochizuki, D. Y., Urdal, D. L., Gillis, S., and Henney, C. S. The treatment of induced immune deficiency with interleukin-2. Immunol. Lett., 10: 307-314, 1985.
28. Ades, E. W., Hinson, N. A., and Butler, L. D. Natural cytolytic activity in mice with natural or induced cellular defects. I. Differential ability of in vitro interleukin-2 addition to augment natural cytolytic function. Cell. Immunol., 101: 15-23. 1986.
29. Bailas, Z. K. Lymphokine-activated killer (LAK) cells. I. DifTerential recovery of LAK. natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide. J. Immunol., 137(7): 2380-2384, 1986.
30. Bailas, Z. K., Rasmussen, W., and Van Otegham, J. K. Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor sub populations. J. Immunol., 138(5): 1647-1652, 1987.
31. Merluzzi, V. J., Smith, M. D., and Last-Barney, K. Similarities and distinctions between murine natural killer cells and lymphokine activated killer cells. Cell Immunol., 100: 563-569, 1986.
32. Marder, P., and Schmidtke, J. Cyclosporin A inhibits helper/inducer surface antigen expression of activated human lymphocytes. Int. J. Immunopharm., 7: 165-175, 1985.
33. Butler, L. D., DeRiso, P. E., Marder, P., and Scheetz, M. In vivoexpression and regulation of murine IL-2 receptors after antigen sensitization. J. Immunol., 138: 470-477. 1987.
34. Butler, L. D., Browne, C. P., Hinson, N. A., and Ades, E. W. Ability of recombinant interleukin-2 to enhance natural killer cells function in immunodeficiency states. In: E. Lotzova and R. Herberman (eds.). Natural Immunity Cancer and Biological Response Modification, pp. 143-152. New York: Karger, 1986.
35. Depper, J., Leonard, W. J., Drogula, C., Kronke. M., Waldmann, T. A., and Greene, W. C. Interleukin-2 (IL-2) augments transcription of the II-2 receptorgene. Proc. Nati. Acad. Sci. USA, 82: 4230-4234, 1985.
36. Reem, G., Yeh, N., Urdal, D. L., Kilian, P. L., and Parrar, J. J. Induction and upregulation by interleukin-2 of high affinity interleukin-2 receptors on thymocytes and T cells. Proc. Nati. Acad. Sci. USA, 82: 8663-8666, 1985.
37. Tsudo, M., Kozak, R. W., Goldman, C. K., and Waldmann, T. A. Demonstration of a non-Tac peptide that binds interleukin 2: A potential participant in a multichain interleukin 2 receptor complex. Proc. Nati. Acad. Sci. USA, 83: 9694, 1986.
38. Teshigawara, K., Wang, H. M., Kato, K., and Smith, K. A. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J. Exp. Med., 165: 223-238, 1987.
39. Rosenstein, M., Ettinghausen, S. E., and Rosenberg, S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol., 137: 1735-1742, 1986.
40. Rosenberg, S. A., Lotze, M. J., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Roberston, C. W., Lee, R. E., and Rubin, J. T., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 and high dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.